\begin{tabular}{rllccccc}
\toprule
{} &                                               Symbol &                                      Set &  \# Peptides & HLA-I Coverage & HLA-II Coverage & Total Coverage &  \# B-cell Epitope Regions \\
\midrule
0  &                                      $ \circledast $ &                                CD4+/CD8+ &            3 &         84.9\% &          84.7\% &         71.9\% &                          0 \\
1  &                                    $ \circledast^d $ &               CD4+/CD8+ (H2$^d$ ligands) &            4 &         90.2\% &          84.7\% &         76.4\% &                          0 \\
2  &                                    $ \circledast^b $ &               CD4+/CD8+ (H2$^b$ ligands) &            4 &         93.9\% &          84.7\% &         79.5\% &                          0 \\
3  &                                 $ \circledast^{bd} $ &    CD4+/CD8+ (H2$^b$ and H2$^d$ ligands) &            4 &         92.1\% &          84.7\% &         78.0\% &                          0 \\
4  &                                            $ \circ $ &                                     CD4+ &            3 &         92.2\% &          88.5\% &         81.6\% &                          0 \\
5  &                                          $ \circ^d $ &                    CD4+ (H2$^d$ ligands) &            3 &         92.2\% &          88.5\% &         81.6\% &                          0 \\
6  &                                          $ \circ^b $ &                    CD4+ (H2$^b$ ligands) &            3 &         69.5\% &          84.7\% &         58.9\% &                          0 \\
7  &                                       $ \circ^{bd} $ &         CD4+ (H2$^b$ and H2$^d$ ligands) &            3 &         93.8\% &          84.7\% &         79.4\% &                          0 \\
8  &                                             $ \ast $ &                                     CD8+ &            3 &         95.1\% &          62.2\% &         59.1\% &                          0 \\
9  &                                           $ \ast^d $ &                    CD8+ (H2$^d$ ligands) &            3 &         94.7\% &          68.9\% &         65.3\% &                          0 \\
10 &                                           $ \ast^b $ &                    CD8+ (H2$^b$ ligands) &            3 &         94.7\% &          68.9\% &         65.3\% &                          0 \\
11 &                                        $ \ast^{bd} $ &         CD8+ (H2$^b$ and H2$^d$ ligands) &            3 &         94.7\% &          68.9\% &         65.3\% &                          0 \\
12 &  $ \setlength{\fboxsep}{0.5pt} \boxed{\circledast} $ &                         B-Cell/CD4+/CD8+ &            4 &         84.2\% &          62.7\% &         52.8\% &                          3 \\
13 &                                       $ \boxcircle $ &                              B-Cell/CD4+ &            4 &         84.2\% &          62.7\% &         52.8\% &                          3 \\
14 &                                     $ \boxcircle^b $ &             B-Cell/CD4+ (H2$^b$ ligands) &            2 &         37.2\% &          39.4\% &         14.6\% &                          2 \\
15 &                                          $ \boxast $ &                              B-Cell/CD8+ &            3 &         88.9\% &          22.6\% &         20.1\% &                          3 \\
16 &                                        $ \boxast^d $ &             B-Cell/CD8+ (H2$^d$ ligands) &            1 &         77.2\% &          38.4\% &         29.7\% &                          1 \\
17 &                                        $ \boxast^b $ &             B-Cell/CD8+ (H2$^b$ ligands) &            2 &         87.2\% &          22.6\% &         19.7\% &                          2 \\
18 &                                     $ \boxast^{bd} $ &  B-Cell/CD8+ (H2$^b$ and H2$^d$ ligands) &            1 &         77.2\% &          38.4\% &         29.7\% &                          1 \\
19 &                                        $ \boxempty $ &                                   B-Cell &            3 &         78.0\% &          40.7\% &         31.8\% &                          3 \\
20 &                                      $ \boxempty^d $ &                  B-Cell (H2$^d$ ligands) &            3 &         78.0\% &          40.7\% &         31.8\% &                          3 \\
21 &                                      $ \boxempty^b $ &                  B-Cell (H2$^b$ ligands) &            3 &         78.0\% &          40.7\% &         31.8\% &                          3 \\
22 &                                   $ \boxempty^{bd} $ &       B-Cell (H2$^b$ and H2$^d$ ligands) &            3 &         78.0\% &          40.7\% &         31.8\% &                          3 \\
\bottomrule
\end{tabular}
